118 related articles for article (PubMed ID: 14734454)
1. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma.
Mitchell MS; Kan-Mitchell J; Morrow PR; Darrah D; Jones VE; Mescher MF
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):76-83. PubMed ID: 14734454
[TBL] [Abstract][Full Text] [Related]
2. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
[TBL] [Abstract][Full Text] [Related]
3. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant.
Mitchell MS; Kan-Mitchell J; Kempf RA; Harel W; Shau HY; Lind S
Cancer Res; 1988 Oct; 48(20):5883-93. PubMed ID: 3262416
[TBL] [Abstract][Full Text] [Related]
4. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma.
Dudek AZ; Mescher MF; Okazaki I; Math VT; Luo X; Curtsinger JM; Miller JS
Am J Clin Oncol; 2008 Apr; 31(2):173-81. PubMed ID: 18391603
[TBL] [Abstract][Full Text] [Related]
5. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
6. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients.
Zajac P; Oertli D; Marti W; Adamina M; Bolli M; Guller U; Noppen C; Padovan E; Schultz-Thater E; Heberer M; Spagnoli G
Hum Gene Ther; 2003 Nov; 14(16):1497-510. PubMed ID: 14577912
[TBL] [Abstract][Full Text] [Related]
8. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin 2-producing melanoma cell line.
Osanto S; Schiphorst PP; Weijl NI; Dijkstra N; Van Wees A; Brouwenstein N; Vaessen N; Van Krieken JH; Hermans J; Cleton FJ; Schrier PI
Hum Gene Ther; 2000 Mar; 11(5):739-50. PubMed ID: 10757353
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.
Slingluff CL; Yamshchikov G; Neese P; Galavotti H; Eastham S; Engelhard VH; Kittlesen D; Deacon D; Hibbitts S; Grosh WW; Petroni G; Cohen R; Wiernasz C; Patterson JW; Conway BP; Ross WG
Clin Cancer Res; 2001 Oct; 7(10):3012-24. PubMed ID: 11595689
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
11. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells.
van Baren N; Bonnet MC; Dréno B; Khammari A; Dorval T; Piperno-Neumann S; Liénard D; Speiser D; Marchand M; Brichard VG; Escudier B; Négrier S; Dietrich PY; Maraninchi D; Osanto S; Meyer RG; Ritter G; Moingeon P; Tartaglia J; van der Bruggen P; Coulie PG; Boon T
J Clin Oncol; 2005 Dec; 23(35):9008-21. PubMed ID: 16061912
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
13. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells.
Nestle FO; Alijagic S; Gilliet M; Sun Y; Grabbe S; Dummer R; Burg G; Schadendorf D
Nat Med; 1998 Mar; 4(3):328-32. PubMed ID: 9500607
[TBL] [Abstract][Full Text] [Related]
14. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens.
Germeau C; Ma W; Schiavetti F; Lurquin C; Henry E; Vigneron N; Brasseur F; Lethé B; De Plaen E; Velu T; Boon T; Coulie PG
J Exp Med; 2005 Jan; 201(2):241-8. PubMed ID: 15657293
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
[TBL] [Abstract][Full Text] [Related]
16. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
17. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
18. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
Banchereau J; Palucka AK; Dhodapkar M; Burkeholder S; Taquet N; Rolland A; Taquet S; Coquery S; Wittkowski KM; Bhardwaj N; Pineiro L; Steinman R; Fay J
Cancer Res; 2001 Sep; 61(17):6451-8. PubMed ID: 11522640
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma.
Duval L; Schmidt H; Kaltoft K; Fode K; Jensen JJ; Sorensen SM; Nishimura MI; von der Maase H
Clin Cancer Res; 2006 Feb; 12(4):1229-36. PubMed ID: 16489078
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma.
Wang F; Bade E; Kuniyoshi C; Spears L; Jeffery G; Marty V; Groshen S; Weber J
Clin Cancer Res; 1999 Oct; 5(10):2756-65. PubMed ID: 10537339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
